A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis
To evaluate the efficacy and safety of tacrolimus capsules in patients with myasthenia gravis who are inadequately treated by glucocorticoid.
Myasthenia Gravis
DRUG: Tacrolimus capsule|DRUG: Placebo
Change from baseline in quantitative myasthenia gravis (QMG) score for disease severity, Baseline and at 24 weeks|Change from baseline in QMG score for disease severity, Baseline and at 4 weeks|Change from baseline in QMG score for disease severity, Baseline and at 8 weeks|Change from baseline in QMG score for disease severity, Baseline and at 12 weeks|Change from baseline in QMG score for disease severity, Baseline and at 16 weeks|Change from baseline in QMG score for disease severity, Baseline and at 20 weeks
Changes in Osserman classification, Baseline and at 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks and 24 weeks|Changes in myasthenia gravis activity of daily living scale, Baseline and at 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks and 24 weeks
To evaluate the efficacy and safety of tacrolimus capsules in patients with myasthenia gravis who are inadequately treated by glucocorticoid.